Puma Biotechnology Inc. (PBYI) announced Tuesday morning that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive trend vote recommending the approval of neratinib. Neratinib is a treatment for early stage HER2-positive hormone receptor positive breast cancer.
from RTT - Before the Bell https://ift.tt/2Ks0gae
via IFTTT
No comments:
Post a Comment